The new Acuity Break-Away Lead Delivery System, developed by Boston Scientific, has received clearance from the US Food and Drug Administration (FDA).
The Acuity Break-Away is used with cardiac resynchronisation therapy defibrillators (CRT-Ds) and cardiac resynchronisation therapy pacemakers (CRT-Ps) to treat heart failure.
The solution inserts leads – insulated wires that carry heart signals to the implanted device – into the heart through the veins.
The system places leads in veins of varying sizes, including difficult-to-access veins.
The system features an integrated, break-away hemostasis valve to minimise blood loss and allow for a streamlined implant experience using fewer steps and instruments during surgery.